Core Viewpoint - Guizhou Sanli Pharmaceutical Co., Ltd. plans to sign technology transfer and development contracts with Guangdong Pharmaceutical University to enhance its product portfolio and market competitiveness through collaboration in drug research and development [1][5]. Group 1: Contract Overview - The company intends to sign a technology transfer contract for a fibrosis invention patent, successfully acquiring it for RMB 50 million on June 11, 2025 [2][3]. - The total amount for the proposed technology contracts is RMB 150 million, which is close to the board's review and disclosure threshold, prompting the management to voluntarily disclose this information [2][5]. - The company held board meetings on June 12, 2025, to approve the contracts, which do not require shareholder approval or constitute a major asset restructuring [2][5]. Group 2: Contract Details - The technology transfer contract involves the transfer of rights for the invention patent related to liver protection and fibrosis treatment, with the company becoming the sole patent owner [3][4]. - The payment structure for the patent transfer includes an initial payment of RMB 5 million within 10 working days after signing, followed by milestone-based payments [3][4]. - The technology development contract focuses on the joint development of SL&GDPU-001, a new traditional Chinese medicine, covering non-clinical and clinical research phases [4][5]. Group 3: Impact on the Company - The collaboration aims to leverage the company's industrial capabilities and the university's research resources, aligning with the company's long-term strategic goals [5]. - The contracts are not expected to significantly impact the company's current financial status or operating performance, with future impacts dependent on the progress of the projects [5].

Group 1 - The core point of the announcement is that the company plans to sign a technology transfer and development contract with Guangdong Pharmaceutical University to enhance its product portfolio and market competitiveness through collaboration [1][2] - The total amount of the proposed technology contract is 150 million RMB, which will be paid in installments according to the contract terms [2] - The signing of the contract does not require approval from the shareholders' meeting and does not constitute a related party transaction or a major asset restructuring as per relevant regulations [2] Group 2 - The decision was made during the 12th meeting of the 4th Supervisory Board, which was held in compliance with legal and regulatory requirements [1] - The voting results showed unanimous support with 3 votes in favor, and no votes against or abstaining [2] - The contract aligns with the company's long-term strategic goals and is expected to have no significant impact on the current financial status or operating performance [2]